

# Index

## A

- Academic freedom, fair criticism versus politicization of neuroscience of sex differences, 2–5
- ACTH. *See* Adrenocorticotrophic hormone
- AD. *See* Alzheimer's disease
- Adalimumab, adverse drug reactions, 26
- Adrenocorticotrophic hormone (ACTH)
  - circadian rhythm, 63
  - sex differences, 73–75, 88
- ADRs. *See* Adverse drug reactions
- Adverse drug reactions (ADRs), sex differences, 22–29
- AIS. *See* Androgen insensitivity syndrome
- Aliskiren, adverse drug reactions, 25
- Alzheimer's disease (AD), 149–150
- AMH. *See* Anti-Müllerian hormone
- Amlodipine, adverse drug reactions, 25
- Amygdala, social behavior network, 48
- Androgen insensitivity syndrome (AIS), 134–135
- Androgens
  - depression and stress regulation, 95–96
  - hypothalamic-pituitary-adrenal axis regulation, 75, 80
  - perinatal androgens and sex bias of mast cell diseases
    - brain development and mast cell activity, 108–109
    - immunoglobulin E-mediated anaphylaxis, 107–108
    - mast cell granule mediator storage, 108
  - prenatal exposure. *See* Digit ratio
- Anteroventral periventricular nucleus (AVPV), sex differences, 50, 63
- Anti-Müllerian hormone (AMH), 134–135
- Arginine vasopressin (AVP)
  - hypothalamic-pituitary-adrenal axis regulation, 73–74
  - spotted hyena sex differences, 127
- Aripiprazole, adverse drug reactions, 27
- Aspirin, adverse drug reactions, 25
- AVP. *See* Arginine vasopressin
- AVPV. *See* Anteroventral periventricular nucleus

## B

- Basolateral amygdala (BLA), 90, 92
- Bed nucleus of the stria terminalis (BNST)
  - sex differences, 42, 50–51, 53, 55
  - social behavior network, 48–49
  - stress response, 88, 94
- Behavior, sex differences
  - automated phenotyping to assess internal and affective states, 40–41
  - multimodal data stream incorporation, 39
  - overview, 33–34, 36
  - quantification without bias
    - automation, 37–39
    - historical perspective, 36–37
    - machine learning, 37–38
  - tools for discovery, 35
- BICCN. *See* BRAIN Initiative Cell Census Network
- BLA. *See* Basolateral amygdala
- Blood pressure, circadian rhythm, 64
- BNST. *See* Bed nucleus of the stria terminalis
- Body temperature, circadian rhythm, 64–65
- BRAIN Initiative Cell Census Network (BICCN), 51
- Brain organization theory, 6
- Buprenorphine, adverse drug reactions, 26
- Bupropion, adverse drug reactions, 27

## C

- CAH. *See* Congenital adrenal hyperplasia
- Cannabis, adverse drug reactions, 28
- Capecitabine, adverse drug reactions, 26
- Carbamazepine, adverse drug reactions, 26
- Chronic social defeat stress (CSDS), 86–88
- Circadian rhythm, sex differences
  - blood pressure, 64
  - body temperature, 64–65
  - disruption effects, 66–67
  - heart rate variability, 63–64
  - hypothalamic pituitary adrenal axis, 62
  - hypothalamic pituitary gonadal axis, 62–63
  - immune response, 65
  - neuroanatomy, 62
  - overview, 61–62
  - prospects for study, 67
  - sleep–wake rhythms, 65–66

## Index

- Citalopram, adverse drug reactions, 27  
Clopidogrel, adverse drug reactions, 25  
Clozapine, adverse drug reactions, 27  
Congenital adrenal hyperplasia (CAH), 6–8,  
132, 134–135  
COVID-19  
cell lines for study, 23  
sex differences, 111  
CRISPR, 54  
CSDS. *See* Chronic social defeat stress  
CUT&RUN, 54  
Cyclosporin, adverse drug reactions, 26
- D**
- Dabigatran, adverse drug reactions, 25  
Darifenacin, adverse drug reactions, 25  
Darting behavior, sex differences, 35, 40  
mapping to sex differences in nervous  
system, 41–42  
sex differences as individual differences, 42  
DeepLabCut, 35, 37  
DeepPoseKit, 37  
DeepSqueak, 39  
Dentate gyrus (DG), 89, 91  
Depression. *See* Major depressive disorder  
Developmental systems theory, 6–7  
DG. *See* Dentate gyrus  
Diazepam, adverse drug reactions, 27  
Digit ratio  
androgen insensitivity syndrome, 134–135  
gay men, 136–139  
lesbians, 135  
sensitivity as individual difference measure, 9  
Digoxin, adverse drug reactions, 25  
Dihydrotestosterone. *See* Androgens  
Dofetilide, adverse drug reactions, 25
- E**
- EAE. *See* Experimental autoimmune  
encephalomyelitis  
Elevated plus maze (EPM), 87  
Epigenetics, brain sexual differentiation  
ER $\alpha$  neural targets, 53–54  
gene expression, sex differences, 53  
neural circuit organization, 48–51  
neuron dimorphism and cell identity, 51  
overview, 48, 51–53  
prospects for study, 55–56  
EPM. *See* Elevated plus maze  
ERP. *See* Event-related potential  
Erythromycin, adverse drug reactions, 26  
ER $\alpha$ . *See* Estrogen receptor  $\alpha$
- Estradiol  
hypothalamic-pituitary-adrenal axis modulation,  
74–75, 79–80  
mast cell response, 109  
Estrogen receptor  $\alpha$  (ER $\alpha$ )  
gene regulatory signature in perinatal period,  
54–55  
hypothalamic-pituitary-adrenal axis sex  
differences, 75, 80  
neural targets, 53–54  
Eszopiclone, adverse drug reactions, 27  
Event-related potential (ERP), sex differences in  
stress response, 79  
Experimental autoimmune encephalomyelitis  
(EAE), sex differences, 106–107
- F**
- FCG model. *See* Four core genotypes model  
Female rodents  
exclusion from preclinical studies, 16, 19–22  
HPA axis. *See* Hypothalamic-pituitary-adrenal  
axis  
trait variability, 19–20  
Finasteride, spotted hyena development studies, 122,  
126–127  
Fluorouracil, adverse drug reactions, 26  
Fluoxetine, adverse drug reactions, 27  
Flutamide, spotted hyena development studies,  
122, 126  
fMRI. *See* Functional magnetic resonance  
imaging  
Forced swim test (FST), 87, 95–96  
Four core genotypes (FCG) model, 149–150  
FST. *See* Forced swim test  
Functional magnetic resonance imaging (fMRI)  
hippocampus–nucleus accumbens  
connectivity, 92  
Trier Social Stress Test studies, 78
- G**
- Gabapentin, adverse drug reactions, 26  
Gonadotropin-releasing hormone. *See* Isolated  
gonadotropin-releasing hormone  
deficiency
- H**
- hCG. *See* Human chorionic gonadotropin  
Heart rate variability, circadian rhythm, 63–64  
Heparin, adverse drug reactions, 25  
Hippocampus, stress, depression, and sex differences,  
91–94

- HPA axis. *See* Hypothalamic-pituitary-adrenal axis
- Human chorionic gonadotropin (hCG), 139–140
- Hypothalamic-pituitary-adrenal (HPA) axis. *See also* Stress response
- circadian rhythm, 62
  - human studies of sex differences, 76–79
  - prospects for study, 79–80
  - rodent studies
    - regulation, 72–73
    - sex differences
      - androgen regulation, 75, 80
      - estradiol modulation, 74–75
      - functional differences, 73–74, 88–91
      - negative feedback regulation, 74
      - organized actions of gonadal steroids, 75–76
- I**
- IGD. *See* Isolated gonadotropin-releasing hormone deficiency
- Imipramine, adverse drug reactions, 27
- Immune response, circadian rhythm, 65
- Immunoglobulin E-mediated anaphylaxis, sex differences, 105–106
- Inductive risk, fair criticism versus politicization of neuroscience of sex differences, 8–11
- Infliximab, adverse drug reactions, 26
- Interactive objectivity, 7–8
- Isolated gonadotropin-releasing hormone deficiency (IGD)
  - androgen exposure in development, 139–140
  - sexual orientation, 140–142
- K**
- Kdm5c*, 154
- Kdm6a*, 150
- Ketamine, adverse drug reactions, 26
- L**
- LEAP, 37
- Levofloxacin, adverse drug reactions, 26
- LH. *See* Luteinizing hormone
- Liraglutide, adverse drug reactions, 25
- Long-term depression (LTD), 92
- Long-term potentiation (LTP), 93–94
- Losartan, adverse drug reactions, 25
- LTD. *See* Long-term depression
- LTP. *See* Long-term potentiation
- Luteinizing hormone (LH), circadian rhythm, 63
- M**
- Major depressive disorder (MDD)
  - animal models, 86–88
  - sex differences in rates, 86
  - stress response
    - depression, and sex differences
      - hippocampus, 91–94
      - hormone signaling in brain, 94–96
      - nucleus accumbens, 91–94
      - prospects for study, 96–97
    - sex differences, 88–91
- MAP-2, 96
- MARS, 37
- Mast cell
  - estrous cycle and estrogen effects on mast cell numbers, 109
  - evolutionary perspective of sex differences, 111
  - functional overview, 103–104
  - prospects for study, 111–113
  - sex chromosome complement influences, 110–111
  - sex differences in diseases
    - experimental autoimmune encephalomyelitis, 106–107
    - immunoglobulin E-mediated anaphylaxis, 105–106
    - multiple sclerosis, 106–107
    - perinatal androgens and sex bias of diseases
      - brain development and mast cell activity, 108–109
      - immunoglobulin E-mediated anaphylaxis, 107–108
      - mast cell granule mediator storage, 108
    - sex hormone interactions, 109–110
- MDD. *See* Major depressive disorder
- MDMA, adverse drug reactions, 28
- Medial prefrontal cortex (mPFC), 90, 95
- Medial preoptic area (MPOA)
  - sex differences, 108–109
  - social behavior network, 49–50
- Methylphenidate, adverse drug reactions, 27
- Mirabegron, adverse drug reactions, 25
- Morphine, adverse drug reactions, 26
- mPFC. *See* Medial prefrontal cortex
- MPOA. *See* Medial preoptic area
- MS. *See* Multiple sclerosis
- Multiple sclerosis (MS), sex differences, 106–107
- MUPET, 39
- N**
- NAc. *See* Nucleus accumbens
- Nortriptyline, adverse drug reactions, 27

Index

- NPX, 155
- Nucleus accumbens (NAc)  
sex differences, 42  
stress, depression, and sex differences, 91–94
- O**
- Olanzapine, adverse drug reactions, 27
- Onuf's nucleus, spotted hyena, 126–127
- Oxycodone, adverse drug reactions, 26
- P**
- Paclitaxel, adverse drug reactions, 26
- PAG. *See* Periaqueductal gray
- PAR. *See* Pseudoautosomal region
- Paraventricular nucleus (PVN), hypothalamic-pituitary-adrenal axis sex differences, 73–76, 88
- Perampanel, adverse drug reactions, 26
- Periaqueductal gray (PAG), sex differences, 41
- Pharmacokinetics, sex differences, 22–29
- Politicization, neuroscience of sex differences  
academic freedom versus equality, 2–5  
fair criticism distinguishing, 4–5, 7–11  
frameworks, background assumptions and dominant methodologies, 5–8  
inductive risks and social values, 8–10  
overview, 1–2
- Posttraumatic stress disorder (PTSD), 91
- Pramipexole, adverse drug reactions, 26
- Pravastatin, adverse drug reactions, 25
- Prednisone, adverse drug reactions, 26
- Primaquine, adverse drug reactions, 28
- Propranolol, adverse drug reactions, 25
- Pseudoautosomal region (PAR), X chromosome, 155
- PTSD. *See* Posttraumatic stress disorder
- PVN. *See* Paraventricular nucleus
- R**
- Ranitidine, adverse drug reactions, 25
- Risperidone, adverse drug reactions, 27
- Rosiglitazone, adverse drug reactions, 25
- S**
- SABV. *See* Sex as a biological variable
- SCN. *See* Suprachiasmatic nucleus of the hypothalamus
- SCVS. *See* Subchronic variable stress
- SDN-POA. *See* Sexually dimorphic nucleus
- Sertraline, adverse drug reactions, 27
- Sex as a biological variable (SABV), 16, 34
- Sex-based analysis, historical perspective, 17–19
- Sex bias, historical perspective, 16–17
- Sexual differentiation  
cell-autonomous sex chromosome effects, 148–151  
divergence of genetic and hormonal conceptual frameworks, 151–152  
education, 155, 157  
evolution  
compensation for other sex differences, 153–155  
sex differences in genome, 152  
four core genotypes model, 149–150  
nongonadal sexual dimorphism on X chromosome, 155–156  
two-step hormonal theory, 147–148, 151
- Sexual orientation. *See* Digit ratio; Isolated gonadotropin-releasing hormone deficiency
- Sexually dimorphic nucleus (SDN-POA), 48–51, 55–56
- Sleep–wake rhythm, sex differences, 65–66
- Spotted hyena, sex differences  
behavior  
aggression and dominance, 119–121  
development of aggression behavior differences, 121–123  
reproduction, 118–119  
space use, 118  
morphology  
body size and shape, 123  
genitalia, 123–126  
nervous system, 126–128  
overview, 117–118, 128–129
- Sry, 147–149, 152–154
- Stress response. *See also* Hypothalamic-pituitary-adrenal axis  
depression, stress, and sex differences  
hippocampus, 91–94  
hormone signaling in brain, 94–96  
nucleus accumbens, 91–94  
prospects for study, 96–97  
human studies of sex differences, 76–79  
overview, 71–72  
rodent studies of hypothalamic-pituitary-adrenal axis  
regulation, 72–73  
sex differences  
androgen regulation, 75  
estradiol modulation, 74–75  
functional differences, 73–74, 88–91  
negative feedback regulation, 74  
organized actions of gonadal steroids, 75–76

Subchronic variable stress (SCVS),

86, 88, 94

Suprachiasmatic nucleus of the

hypothalamus (SCN)

circadian rhythm control, 61–62

sex differences, 62–63, 66

## T

Terfenadine, adverse drug reactions, 28

Testosterone. *See also* Androgens

fetal metabolism, 48

hypothalamic-pituitary-adrenal axis modulation,

75–76

mast cell interactions, 110

Torasemide, adverse drug reactions, 25

Tramadol, adverse drug reactions, 26

Trier Social Stress Test (TSST), sex differences,

77–78

Tropium, adverse drug reactions, 25

TSST. *See* Trier Social Stress Test

## V

Ventromedial hypothalamus

sex differences, 41–42, 49–50

social behavior network, 49

Verapamil, adverse drug reactions, 25

Vigilance behavior, sex differences, 35, 40–41

Voriconazole, adverse drug reactions, 26

## W

Warfarin, adverse drug reactions, 25

## X

X chromosome, nongonadal sexual dimorphism,

155–156

*Xist*, 151

## Z

Zolmitriptan, adverse drug reactions, 26

Zolpidem, adverse drug reactions, 27